Lutetium texaphyrin: A photocatalyst that triggers pyroptosis via biomolecular photoredox catalysis
- PMID: 38381784
- PMCID: PMC10907263
- DOI: 10.1073/pnas.2314620121
Lutetium texaphyrin: A photocatalyst that triggers pyroptosis via biomolecular photoredox catalysis
Abstract
Photon-controlled pyroptosis activation (PhotoPyro) is a promising technique for cancer immunotherapy due to its noninvasive nature, precise control, and ease of operation. Here, we report that biomolecular photoredox catalysis in cells might be an important mechanism underlying PhotoPyro. Our findings reveal that the photocatalyst lutetium texaphyrin (MLu) facilitates rapid and direct photoredox oxidation of nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate, and various amino acids, thereby triggering pyroptosis through the caspase 3/GSDME pathway. This mechanism is distinct from the well-established role of MLu as a photodynamic therapy sensitizer in cells. Two analogs of MLu, bearing different coordinated central metal cations, were also explored as controls. The first control, gadolinium texaphyrin (MGd), is a weak photocatalyst but generates reactive oxygen species (ROS) efficiently. The second control, manganese texaphyrin (MMn), is ineffective as both a photocatalyst and a ROS generator. Neither MGd nor MMn was found to trigger pyroptosis under the conditions where MLu was active. Even in the presence of a ROS scavenger, treating MDA-MB-231 cells with MLu at concentrations as low as 50 nM still allows for pyroptosis photo-activation. The present findings highlight how biomolecular photoredox catalysis could contribute to pyroptosis activation by mechanisms largely independent of ROS.
Keywords: NAD(P)H; NIR photocatalyst; PhotoPyro; photoredox catalysis; pyroptosis.
Conflict of interest statement
Competing interests statement:J.L.S. is a cofounder of a new startup, InnovoTEX, Inc. As yet, the position in uncompensated, either with money or stock. However, in the near future an equity grant is anticipated. No funding from InnovoTEX comes to J.L.S.’s or any of the authors’ laboratories.
Figures





References
-
- Ryu K. A., Kaszuba C. M., Bissonnette N. B., Oslund R. C., Fadeyi O. O., Interrogating biological systems using visible-light-powered catalysis. Nat. Rev. Chem. 5, 322–337 (2021). - PubMed
-
- Xiong H., et al. , Photo-controllable biochemistry: Exploiting the photocages in phototherapeutic window. Chem 9, 29–64 (2023).
-
- Hüll K., Morstein J., Trauner D., In vivo photopharmacology. Chem. Rev. 118, 10710–10747 (2018). - PubMed
-
- Xu Y., et al. , Photodynamic Alzheimer’s disease therapy: From molecular catalysis to photo-nanomedicine. Coordin. Chem. Rev. 470, 214726 (2022).
-
- Li M., et al. , Superoxide radical photogenerator with amplification effect: Surmounting the Achilles’ heels of photodynamic oncotherapy. J. Am. Chem. Soc. 141, 2695–2702 (2019). - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous